Adequate hemodialysis does not compromise the cardioprotective effect of agalsidase alfa on patients with Fabry disease: a case report
Patients with Fabry disease who are on renal replacement therapy may benefit from enzyme replacement therapy. Moreover, adequate hemodialysis does not compromise the cardioprotective effect of agalsidase-α.
Authors
- Xiansen Wei
- Hong Jiang (ORCID: https://orcid.org/0000-0002-3745-5549)
- Wenge Li (ORCID: https://orcid.org/0000-0002-4749-1009)
- Li Zhuo (ORCID: https://orcid.org/0000-0003-2028-6168)
- Shimin Jiang (ORCID: https://orcid.org/0000-0001-5265-7395)
Institutions
- China-Japan Friendship Hospital (CN)
Publication Details
- Journal
- Journal of Medical Case Reports
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1186/s13256-025-05488-5
- Primary Topic
- Lysosomal Storage Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00